144 related articles for article (PubMed ID: 31107542)
1. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter rectal arterial chemoembolization with oxaliplatin plus S-1 concurrent chemoradiotherapy can improve the pathological remission rate in locally advanced rectal cancer: a comparative study.
Yang B; Shan J; Feng Y; Dai N; Li M; Chen C; He S; Wang G; Xiao H; Li C; Wang D
Radiat Oncol; 2020 May; 15(1):94. PubMed ID: 32375814
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer.
Yang XH; Li KG; Wei JB; Wu CH; Liang SX; Mo XW; Chen JS; Tang WZ; Qu S
Sci Rep; 2020 Jul; 10(1):12539. PubMed ID: 32719436
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
Gérard JP; Azria D; Gourgou-Bourgade S; Martel-Lafay I; Hennequin C; Etienne PL; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah JF; Mahé MA; Bécouarn Y; Dupuis O; Lledo G; Seitz JF; Bedenne L; Juzyna B; Conroy T
J Clin Oncol; 2012 Dec; 30(36):4558-65. PubMed ID: 23109696
[TBL] [Abstract][Full Text] [Related]
5. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
[No Abstract] [Full Text] [Related]
6. [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Qiao Y; Ren H; Huang Y; DU ZL; Yu DK; Jin J; Li YX; Lin DX; Tan W
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):268-72. PubMed ID: 23985254
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
Larsen FO; Markussen A; Jensen BV; Fromm AL; Vistisen KK; Parner VK; Linnemann D; Hansen RH; Johannesen HH; Schou JV
Clin Colorectal Cancer; 2017 Jun; 16(2):e7-e14. PubMed ID: 27743742
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
Cho H; Kim JE; Kim KP; Yu CS; Kim JC; Kim JH; Lee MA; Jang HS; Oh ST; Kim SY; Oh JH; Kim DY; Hong YS; Kim TW
Am J Clin Oncol; 2016 Dec; 39(6):623-629. PubMed ID: 27322695
[TBL] [Abstract][Full Text] [Related]
9. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.
Azria D; Doyen J; Jarlier M; Martel-Lafay I; Hennequin C; Etienne P; Vendrely V; François E; de La Roche G; Bouché O; Mirabel X; Denis B; Mineur L; Berdah J; Mahé M; Bécouarn Y; Dupuis O; Lledo G; Seitz J; Bedenne L; Gourgou-Bourgade S; Juzyna B; Conroy T; Gérard J
Ann Oncol; 2017 Oct; 28(10):2436-2442. PubMed ID: 28961836
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
Huang MY; Huang JJ; Huang CM; Lin CH; Tsai HL; Huang CW; Chai CY; Lin CY; Wang JY
World J Surg; 2017 Nov; 41(11):2884-2897. PubMed ID: 28608017
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
Formica V; Benassi M; Del Vecchio Blanco G; Doldo E; Martano L; Portarena I; Nardecchia A; Lucchetti J; Morelli C; Giudice E; Rossi P; Anselmo A; Sileri P; Sica G; Orlandi A; Santoni R; Roselli M
Med Oncol; 2018 May; 35(6):83. PubMed ID: 29721745
[TBL] [Abstract][Full Text] [Related]
12. The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.
Valentini V; Gambacorta MA; Cellini F; Aristei C; Coco C; Barbaro B; Alfieri S; D'Ugo D; Persiani R; Deodato F; Crucitti A; Lupattelli M; Mantello G; Navarria F; Belluco C; Buonadonna A; Boso C; Lonardi S; Caravatta L; Barba MC; Vecchio FM; Maranzano E; Genovesi D; Doglietto GB; Morganti AG; La Torre G; Pucciarelli S; De Paoli A
Radiother Oncol; 2019 May; 134():110-118. PubMed ID: 31005204
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03.
Kim SY; Joo J; Kim TW; Hong YS; Kim JE; Hwang IG; Kim BG; Lee KW; Kim JW; Oh HS; Ahn JB; Zang DY; Kim DY; Oh JH; Baek JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):889-899. PubMed ID: 29976501
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
18. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
19. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience.
DE Felice F; Siniscalchi B; Bulzonetti N; Caiazzo R; Musio D; Tombolini V
Anticancer Res; 2019 Dec; 39(12):6957-6963. PubMed ID: 31810967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
